trending Market Intelligence /marketintelligence/en/news-insights/trending/xyldvcgqzfful68u2or0lq2 content esgSubNav
In This List

Medovex acquires lung disease therapy provider

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Medovex acquires lung disease therapy provider

MedoveX Corp. has made its first acquisition under newly appointed CEO William Horne.

The Alpharetta, Ga.-based company — formed to acquire and develop a portfolio of medical technology products and services — said it entered a definitive agreement to acquire the pulmonary biomedical services and patient delivery platform of Regenerative Medicine Solutions LLC in an all-stock deal.

The acquisition reunites Laser Spine Institute's executive management team with Horne, who founded the medical device company and served as its CEO.

Regenerative Medicine Solutions is a Tampa, Fla.-based biomedical services company that manages all five clinics of Lung Health Institute, a provider of cellular therapies to treat chronic obstructive pulmonary disease, or COPD, and other chronic lung disorders.

COPD is the fourth-leading cause of disability in the U.S.

With more than $32 billion spent on COPD-related patient care in 2010, those costs are projected to increase to $49 billion by 2020, according to Medovex.